Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nituzumab and Serplulimab with SBRT in recurrent advanced cervical cancer
NCT06455072Phase 2Recruiting
- Sponsor
- Fujian Medical University Cancer Hospital
- Start
- Feb 2023
- Primary completion
- Jan 2025
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of nimotuzumab, serplulimab in Cervical Cancer (CC), sponsored by Fujian Medical University Cancer Hospital. Started Feb 2023; status: recruiting.
02
Drugs
nimotuzumabserplulimab
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06455072.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06455072.